Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

Dong Wang(Binzhou Medical University), Hailing Cheng(Dalian Medical University), Jean J. Zhao(Harvard University), Nan Jiang(Nanfang Hospital), Min Wang(Central South University), Yuan Zhang(Nantong University), Xiaoqing Wang(Roche (China)), Pixu Liu(Dalian Medical University), Xing Bian(Dalian Medical University), Thomas M. Roberts(Dana-Farber Cancer Institute)
Oncotarget
February 21, 2016
Cited by 86


Related Papers